U.S. Life Sciences Stock News

Earlier in February 2026, RingCentral reported fourth-quarter 2025 results showing revenue rising to US$644.03 million and a shift from a net loss to US$22.97 million in net income, issued 2026 guidance calling for US$640–US$645 million in first-quarter revenue and 4%–5% full-year revenue growth, initiated a quarterly US$0.075 dividend, expanded its buyback authorization to US$500 million after repurchasing 31.61 million shares for US$967.01 million, and announced a broad integration of...

Zoom Communications (ZM) is back in the spotlight after its latest quarterly earnings, with revenue ahead of expectations, a rare earnings miss, cautious profit guidance for 2027, new AI products, and a large buyback program. See our latest analysis for Zoom Communications. The 1 day share price return of 2.38% decline and 7 day share price return of 6.24% decline around the earnings release suggest investors are reassessing Zoom Communications' cautious 2027 profit outlook, even though its 1...

Zebra Technologies (ZBRA) is back in focus after EBI Electric adopted its AltiZ 3D sensors for the new Inspector T lumber scanning system, pairing AI models with machine vision to sharpen yield and cost control. See our latest analysis for Zebra Technologies. Those product wins and the recent buyback and guidance update come against a mixed price backdrop, with the latest share price at $239.01, a 1 day share price return of 1.35% but a 1 year total shareholder return decline of 25.19%,...

NRG Energy (NRG) closed out FY 2025 with fourth quarter revenue of US$7.8b and basic EPS of US$0.26, alongside net income of US$50m. Trailing twelve month figures show revenue of US$30.7b, EPS of US$4.09 and net income of US$797m. The company has seen revenue move from US$28.1b to US$30.7b on a trailing basis across the periods provided, with trailing EPS shifting from US$5.14 to US$4.09 over the same window. This sets up a picture where modest top line progress sits against tighter...

If you are trying to figure out whether BeOne Medicines is attractively priced or already reflects its potential, you are in the right place. The stock closed at US$352.23, with a 7 day return of a 0.6% decline, a 30 day return of 4.8%, and longer term returns of 13.2% year to date, 26.5% over 1 year, 46.6% over 3 years and 21.8% over 5 years. These mixed short term and longer term returns often prompt investors to look more closely at what might be driving sentiment and expectations. In...

Steven Madden (SHOO) has just wrapped up FY 2025 with fourth quarter revenue of US$753.7 million and basic EPS of US$0.33, capping off a year where trailing twelve month revenue reached about US$2.5 billion and EPS came in at US$0.63. The company has seen quarterly revenue move from US$553.5 million and EPS of US$0.57 in Q1 2025 through a loss-making Q2, then recover to US$667.9 million and EPS of US$0.29 in Q3, before landing at the latest Q4 figures. As a result, investors are getting a...

If you are wondering whether Arcus Biosciences is attractively priced today, this article walks through what the current share price could imply about the company’s underlying value. The stock last closed at US$20.27, with returns of 4.3% over 7 days, a 9.8% decline over 30 days, a 13.0% decline year to date, a 99.9% gain over 1 year, a 16.4% return over 3 years and a 41.3% decline over 5 years. Recent attention around Arcus Biosciences has largely focused on its pipeline and partnerships in...

Wondering if Texas Roadhouse at about US$181.78 a share still offers value, or if most of the opportunity is already priced in? This article walks through what the numbers are actually saying about the stock. The share price has eased with an estimated 2.7% decline over the last 7 days and a 2.3% decline over the last 30 days, while longer term returns sit at 6.1% year to date and 5.1% over 1 year, with very large gains of 87.6% over 3 years and 111.3% over 5 years. Recent coverage around...

Blackstone (BX) is back in focus after a sharp share price swing, ongoing M&A talks, and fresh analyst commentary led many investors to reassess how its long term plans square with recent volatility. See our latest analysis for Blackstone. Blackstone shares have been under pressure despite continued M&A activity. The 30 day share price return is 21.22% and the year to date share price return is 25.55%, while the 5 year total shareholder return of 101.48% points to a very different long term...

Earlier in February, Booking Holdings reported fourth‑quarter 2025 results showing revenue rising to US$6,349 million and net income to US$1,428 million, alongside announcing a 25‑for‑1 stock split and a new quarterly dividend of US$10.50 per share. The earnings release also highlighted the Transformation Program’s US$550 million in annual cost savings and stronger margins, underlining how cost discipline is reshaping Booking’s profitability profile. With the Transformation Program’s cost...

Nomad Foods (NYSE:NOMD) has set a shareholder capital return plan for 2025 that lifts dividends and share repurchases by 38% year on year. The company is also preparing broad organizational and planning changes for 2026 aimed at performance and value creation. This combination of higher cash returns and a reset year ahead marks a clear shift in how Nomad Foods is approaching capital allocation and its business setup. For investors looking at the frozen foods group today, Nomad Foods trades...

If you are wondering whether Flex shares still offer value after a strong run, this article walks through what the current price might be implying about the company. Flex recently closed at US$65.67, with a 7 day return of a 0.2% decline, a 30 day return of 3.0%, a year to date return of 3.1% and a 1 year return of 65.2%, while the 3 year return is very large and the 5 year return is also very large. Recent news coverage has tended to focus on Flex as an established player in electronics...

Teva Pharmaceutical Industries (NYSE:TEVA) received FDA acceptance of its New Drug Application for a once monthly long acting injectable olanzapine treatment for schizophrenia. The candidate is designed to remove the need for post injection monitoring, which could reduce treatment barriers for patients and providers. Teva also reported positive 44 week extension data for duvakitug in ulcerative colitis and Crohn’s disease, with sustained efficacy and tolerability. Teva enters this news...

Recent Performance Snapshot Huntington Bancshares (HBAN) has recently drawn investor attention as its shares trade around $17.28, with mixed short term returns, including a 1.5% gain over the past day and a small decline over the past week. See our latest analysis for Huntington Bancshares. While the 1-day share price return of 1.53% contrasts with a 3.41% decline over the past week, Huntington Bancshares still shows a 6.21% 90-day share price return and an 11.77% 1-year total shareholder...

Astronics (NasdaqGS: ATRO) reported record fourth quarter results with strong revenue and margin performance. The company highlighted progress on key defense and aerospace programs that support its guidance for 2026. Management pointed to a record backlog and solid demand trends as supports for its multiyear outlook. Astronics, trading at $78.84, has seen the share price rise 39.3% year to date and 295.4% over the past year. Over three and five years, the stock has delivered gains of...

Innoviva (NasdaqGS:INVA) received FDA approval for NUZOLVENCE, a first in class treatment for uncomplicated urogenital gonorrhea. The company announced a US$125 million share repurchase program alongside the approval. These updates point to meaningful shifts in Innoviva's specialty therapeutics focus and capital allocation approach. For you as an investor, NUZOLVENCE adds a new approved therapy to Innoviva's portfolio, aligning with its push in specialty therapeutics. Gonorrhea treatment is...

General American Investors Company, Inc. has reported its full-year 2025 results, posting revenue of US$24.31 million and net income of US$339.84 million for the year ended December 31, 2025. The contrast between relatively modest revenue and very large net income highlights how investment gains can significantly shape this closed-end fund’s financial profile. With this unusually wide gap between revenue and net income, we’ll explore what the latest earnings mean for General American...

LXP Industrial Trust has reported its fourth-quarter and full-year 2025 results, showing lower revenue but higher full-year net income, and confirmed it has repurchased 23,207,370 shares for US$223.45 million since its 2015 buyback authorization. Alongside earnings, the REIT issued 2026 guidance that pairs a wide net income range with much higher Adjusted Company FFO per share expectations, highlighting a growing gap between accounting profits and cash-flow-based performance metrics. We’ll...

Cipher Digital (CIFR) closed out FY 2025 with Q4 revenue of US$59.7 million and a basic EPS loss of US$1.85, alongside a net income loss of US$734.2 million. On a trailing 12 month basis, revenue was US$223.9 million and basic EPS stood at a loss of US$2.15. The company has seen quarterly revenue move from US$42.2 million in Q4 2024 to US$59.7 million in Q4 2025, while EPS shifted from US$0.05 to a loss of US$1.85 over the same period. This sets up a results season where investors will be...

Context for Provident Financial Services (PFS) Provident Financial Services (PFS) has attracted fresh attention after recent share price moves, with the stock roughly flat over the past day but showing mixed returns over the past week, month and past 3 months. See our latest analysis for Provident Financial Services. At a share price of US$21.91, Provident Financial Services has paired a softer 7 day share price return of 4.61% with a stronger 30 day gain of 6.41%. Its 1 year total...

Earlier this week, T1 Energy replaced its chief accounting officer following an immediate termination and expressed support for U.S. Treasury guidance that confirms its eligibility for Section 45X tax credits tied to its domestic solar supply chain plans. The combination of leadership change and reinforced access to key tax incentives has sharpened investor focus on T1 Energy’s governance and policy-linked business model. Next, we’ll examine how the Treasury’s foreign entity of concern...

In the fourth quarter of 2025, Wynn Resorts reported revenue of US$1,865.98 million and net income of US$100.03 million, while also declaring a US$0.25 per-share dividend and later confirming a cyberattack that exposed hundreds of thousands of employee records. The combination of weaker quarterly profitability, an ongoing data breach investigation, and a class-action lawsuit over alleged cybersecurity failures raises fresh questions about Wynn’s risk profile and operational resilience...

Tilray Brands has entered an exclusive multi year licensing deal with Carlsberg Group to produce, market, sell, and distribute Carlsberg, Carlsberg Elephant, and Kronenbourg 1664 beers in the U.S. The agreement covers all U.S. sales channels and is set to begin in January 2027. The move adds a new beer portfolio to Tilray's growing alcohol and lifestyle business. Ticker NasdaqGS:TLRY last closed at $7.83, with the share price showing a 3.3% gain over the past week but a 10.3% decline over...

Why EMCOR Group (EME) Is On Investors’ Radar Today EMCOR Group (EME) has attracted fresh attention after recent trading left the shares around $801.80, prompting investors to reassess the company’s fundamentals, recent returns, and valuation signals. See our latest analysis for EMCOR Group. While EMCOR Group’s share price eased slightly in the latest session, its 30-day share price return of 11.94% and year-to-date gain of 25.55% sit alongside a very large 5-year total shareholder return of...